Drug Pipeline News

Presented at SLEEP 2026, NIRVANA data show a consistent elinzanetant treatment signal across three sleep measurement modalities, extending earlier OASIS trial findings on patient-reported sleep outcomes in menopausal women.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.

An at-home menstrual blood diagnostic platform in development may enable earlier, noninvasive detection of endometriosis.

During clinical validation done by the company, Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results in 16 samples.

These are the top 5 headlines you might have missed in April 2026 from Contemporary OB/GYN.

The expanded label to include use during pregnancy complicated by type 1 diabetes mellitus is based on data from the CIRCUIT trial.

Utepreva LLC has launched a proprietary, FDA-cleared endometrial sampler that combines suction, disruption, and absorption to improve tissue yield in 20-second office procedures.

The letter from the federal agency allows further phase 2 development for refisolone under an investigational new drug application.

Ramu Perni highlights how the "one tube" workflow streamlines obstetric practices by enabling add-on RBC and platelet antigen tests.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

The FDA cleared the Onclarity HPV Self-Collection Kit, allowing patients to collect samples at home for processing via the FDA-cleared BD Onclarity HPV Assay and BD COR System.

The Ringza slow-release vaginal ring has launched in Canada and is designed to be re-used for up to 1 year.

Researchers developed a porous membrane organ-on-a-chip that replicates the human cervix to study how the microbiome and immune system interact with chlamydia and gonorrhea.

Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

From FDA regulatory updates for products related to women's health, to a preview of upcoming annual meetings and conferences, we keep you updated on what's to come in Q2 of 2026.

Livi is a single-use, soft polyurethane foam device cleared by the FDA to absorb semen and vaginal discharge within approximately 60 seconds.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

ENDO-205 is EndoCyclic Therapeutics' lead program and consists of a first-in-class, non-hormonal targeted epeptide therapeutic for endometriosis, according to the company.

Among 2029 women in Scandinavian countries who were followed up for 14 years, vaccine effectiveness was 100%.

Dardik explains how De Novo-cleared AI identifies preterm birth risk in low-risk pregnancies through whole-image analysis.

Kevin Benson highlighted that the TITAN 2 study demonstrates the Altaviva ITNM system as a safe, minimally invasive, and durable solution for real-world patients who have failed prior overactive bladder treatments.

Raquel Dardik explains how the FDA-cleared Delivery Date AI uses unbiased image analysis to provide a precise predicted delivery date without disrupting existing clinical workflows.

The FDA has cleared a cloud-based AI tool that predicts delivery dates solely from ultrasound images.